Literature DB >> 2647828

Aspergillosis.

S M Levitz1.   

Abstract

The wide spectrum of disease states caused by fungi of the genus Aspergillus is dependent in large measure on environmental conditions leading to exposure, and to local and systemic host defenses. Allergic aspergillosis occurs in individuals hypersensitive to the fungus and is treated by immunosuppression, whereas invasive aspergillosis predominates in the severely immunocompromised and is treated with antifungal therapy. Aspergillomas generally arise from saprophytic colonization of a pre-existing pulmonary cavity with Aspergillus, and may be complicated by life-threatening hemoptosis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2647828

Source DB:  PubMed          Journal:  Infect Dis Clin North Am        ISSN: 0891-5520            Impact factor:   5.982


  6 in total

1.  Inhibition and killing of fungi by the polyamine oxidase-polyamine system. Antifungal activity of the PAO-polyamine system.

Authors:  S M Levitz; D J DiBenedetto; R D Diamond
Journal:  Antonie Van Leeuwenhoek       Date:  1990-08       Impact factor: 2.271

2.  Extensive gastrointestinal aspergillosis associated with AIDS.

Authors:  M S Cappell
Journal:  Dig Dis Sci       Date:  1991-10       Impact factor: 3.199

Review 3.  Virulence factors of medically important fungi.

Authors:  L H Hogan; B S Klein; S M Levitz
Journal:  Clin Microbiol Rev       Date:  1996-10       Impact factor: 26.132

4.  Gastrointestinal tract aspergilloma: possible cause of malabsorption.

Authors:  R J Prescott; N Y Haboubi; I E Burton
Journal:  J Clin Pathol       Date:  1994-02       Impact factor: 3.411

5.  First reported case of Aspergillus granulosus infection in a cardiac transplant patient.

Authors:  M G Fakih; G E Barden; C A Oakes; C S Berenson
Journal:  J Clin Microbiol       Date:  1995-02       Impact factor: 5.948

6.  Activation of C3 and binding to Aspergillus fumigatus conidia and hyphae.

Authors:  T R Kozel; M A Wilson; T P Farrell; S M Levitz
Journal:  Infect Immun       Date:  1989-11       Impact factor: 3.441

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.